Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
December 06, 2022 09:15 ET
|
Cassava Sciences, Inc.
Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately...
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
November 22, 2022 12:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
November 18, 2022 13:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
November 07, 2022 09:00 ET
|
Cassava Sciences, Inc.
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN,...
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
November 03, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against...
Cassava Sciences Announces Expansion of Leadership Team
October 27, 2022 09:15 ET
|
Cassava Sciences, Inc.
Chris Cook, A Skilled Litigator, To Join Management Team as General CounselNew Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas, Oct. 27, 2022 (GLOBE...
Cassava Sciences Announces Initiation of an Open-label Extension Study
October 13, 2022 09:15 ET
|
Cassava Sciences, Inc.
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100 mgUp to 1,600 Patients Are Expected to Enroll AUSTIN, Texas,...
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
September 08, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been...
No Evidence of Data Manipulation in Science Publication on Simufilam
August 18, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of...
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
August 03, 2022 09:15 ET
|
Cassava Sciences, Inc.
Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months...